Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain and posture: Insights into neural activation and postural control in people with multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

Beyond GLM: Inter-Subject Variability as a Complementary Approach to Detect Longitudinal Changes in Emotion Processing in Multiple Sclerosis.

Journal of imaging·2026
Same author

Matrix metalloproteinase 2 (MMP-2) and cardiovascular events in atrial fibrillation patients: A nested case control study from the ATHERO-AF cohort.

Thrombosis research·2026
Same author

Advanced Paternal Age Reduces Live Birth Rates in Normospermic Men Undergoing ART: A Large Retrospective Cohort Study.

Andrology·2026
Same author

Optimising the Diagnosis of Sesame Seed Allergy With the Basophil Activation Test.

Allergy·2026
Same author

Reviewer Comment on Skoda et al. "Neuropsychiatric Symptoms and Caregiver Burden in Dementia: A Longitudinal Dyadic Cohort Study".

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

Related Experiment Video

Updated: Apr 30, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K

Multistimulation group therapy in Alzheimer's disease promotes changes in brain functioning.

Francesca Baglio1, Ludovica Griffanti2, Francesca Lea Saibene3

  • 1IRCCS, Don Gnocchi Foundation, Milan, Italy fbaglio@dongnocchi.it.

Neurorehabilitation and Neural Repair
|May 3, 2014
PubMed
Summary

Multidimensional Stimulation group Therapy (MST) improved cognitive and behavioral symptoms in Alzheimer's disease patients. This nonpharmacological approach also enhanced brain activity, suggesting restored neural functioning.

Keywords:
Alzheimer’s diseaseMRIcognitive therapyfunctional MRIlanguagemagnetic resonance imagingoccupational therapyrecreation therapyrehabilitation

More Related Videos

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

2.7K
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
06:34

Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model

Published on: June 2, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 30, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K
A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

2.7K
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
06:34

Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model

Published on: June 2, 2023

1.9K

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychiatry

Background:

  • Alzheimer's disease (AD) presents a significant social challenge with limited disease-modifying treatments.
  • Growing interest exists in nonpharmacological therapies to manage AD symptoms.
  • Current therapeutic strategies often focus on symptom management rather than disease modification.

Purpose of the Study:

  • To introduce and evaluate a novel nonpharmacological intervention, Multidimensional Stimulation group Therapy (MST).
  • To assess the efficacy of MST in improving cognitive, behavioral, and motor functions in individuals with Alzheimer's disease (PWA).
  • To explore the neural underpinnings of MST's effects using functional magnetic resonance imaging (fMRI).

Main Methods:

  • A randomized-controlled study design was employed.
  • Sixty individuals with mild to moderate Alzheimer's disease (AD) were enrolled.
  • Outcomes were measured using neuropsychological tests, neurobehavioral assessments, and fMRI.

Main Results:

  • MST intervention led to a significant reduction in the Neuropsychiatric Inventory scale score.
  • Improvements were observed in the language and memory subscales of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).
  • fMRI data revealed increased brain activations in temporal areas, the right insular cortex, and the thalamus.

Conclusions:

  • Cognitive-behavioral outcomes indicate MST's effectiveness in enhancing the status of people with AD (PWA).
  • fMRI findings suggest that MST contributes to restoring neural functioning.
  • MST shows promise as a beneficial nonpharmacological therapy for Alzheimer's disease.